ABSTRACT NUMBER: ESOC2026A262 STROKE RISK WITH SGLT2I, GLP-1RA, AND DPP-4I IN TYPE 2 DIABETES: REAL-WORLD LONGITUDINAL ESTIMATES IN THE CONTEXT OF TRIAL AND OBSERVATIONAL EVIDENCE

Anastasios Mavridis, Tamar Abzhandadze, Dongni Buvarp, Björn Eliasson, Mia von Euler, Adam Viktorisson, Katharina Stibrant Sunnerhagen · 2026

Read ABSTRACT NUMBER: ESOC2026A262 STROKE RISK WITH SGLT2I, GLP-1RA, AND DPP-4I IN TYPE 2 DIABETES: REAL-WORLD LONGITUDINAL ESTIMATES IN THE CONTEXT OF TRIAL AND OBSERVATIONAL EVIDENCE by Anastasios Mavridis, Tamar Abzhandadze, Dongni Buvarp, Björn Eliasson, Mia von Euler, Adam Viktorisson, Katharina Stibrant Sunnerhagen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146521.txt.

Description

Mavridis and co-authors compare three classes of diabetes drugs for their effect on stroke risk, using records for a whole country. Their 2026 study includes 267,708 people with type 2 diabetes in the Swedish national register from 2010 to 2019. Drug use, other diseases, and lab values were updated over time, and the team used weighted models that handle such changing records.

One class, the GLP-1 drugs, came with a lower risk of stroke, at about four-fifths the rate of non-use. The other two classes showed no clear link either way. Over the follow-up, more than 11,000 people had a stroke caused by a blocked vessel. The pattern matched pooled results from strict trials, which the authors say helps settle a clash between trial and real-world reports.

Catalog record

CREATORAnastasios Mavridis, Tamar Abzhandadze, Dongni Buvarp, Björn Eliasson, Mia von Euler, Adam Viktorisson, Katharina Stibrant Sunnerhagen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13146521

Browse the full library · About the Tower of Babel